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Introduction
A close correlation exists between energy balance, BP regulation, and life expectancy. Caloric excess pro-
motes obesity, arterial hypertension, and premature mortality, whereas reducing dietary calories decreases 
adiposity and arterial BP while extending mean and maximum life span in diverse species (1–3). Moreover, 
caloric restriction protects from and reverses nutritionally induced and aging-related adiposity and arterial 
hypertension in rodents, primates, and human subjects (1, 2). Physiological mechanisms mediating the 
Reduced expression of the plasma membrane citrate transporter INDY (acronym I’m Not Dead, 
Yet) extends life span in lower organisms. Deletion of the mammalian Indy (mIndy) gene in 
rodents improves metabolism via mechanisms akin to caloric restriction, known to lower blood 
pressure (BP) by sympathoadrenal inhibition. We hypothesized that mIndy deletion attenuates 
sympathoadrenal support of BP. Continuous arterial BP and heart rate (HR) were reduced in 
mINDY-KO mice. Concomitantly, urinary catecholamine content was lower, and the decreases in BP 
and HR by mIndy deletion were attenuated after autonomic ganglionic blockade. Catecholamine 
biosynthesis pathways were reduced in mINDY-KO adrenals using unbiased microarray analysis. 
Citrate, the main mINDY substrate, increased catecholamine content in pheochromocytoma 
cells, while pharmacological inhibition of citrate uptake blunted the effect. Our data suggest that 
deletion of mIndy reduces sympathoadrenal support of BP and HR by attenuating catecholamine 
biosynthesis. Deletion of mIndy recapitulates beneficial cardiovascular and metabolic responses to 
caloric restriction, making it an attractive therapeutic target.
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beneficial effects of  reduced calorie availability on BP regulation include reduced activity of  the sympathet-
ic nervous system and renin-angiotensin-aldosterone system, in concert with increased mitochondrial bio-
genesis (1, 2, 4). These data suggest specific links between metabolic and BP regulation. One of  these links 
may be the mammalian Indy gene (mIndy, acronym I’m Not Dead, Yet), which codes for a plasma membrane 
citrate transporter, regulating energy homeostasis and mitochondrial function (5).
Reduced Indy gene expression prolongs life in Drosophila melanogaster and Caenorhabditis elegans by 
mechanisms mimicking caloric restriction (6, 7). We generated a mammalian Indy-knockout model, the 
mINDY-KO mouse, addressing the effect of  mIndy on mammalian physiology. Deletion of  mIndy protected 
mice from many characteristics of  the cardiometabolic syndrome that develop with high-calorie feeding 
and aging, including adiposity, nonalcoholic fatty liver, insulin resistance, and mitochondrial dysfunction 
(8). Similarly, knockdown of  mIndy in rats and mice improved glucose and lipid homeostasis (9, 10). More-
over, unbiased, whole-genome, microarray-based analysis of  hepatic transcriptional regulation of  ad libi-
tum–fed mINDY-KO mice showed that 80% of  pathways were similarly regulated compared with caloric 
restricted wild-type (WT) control mice (8). These data indicate important functional and transcriptional 
similarities between mIndy deletion and caloric restriction. We tested the hypothesis that similar to caloric 
restriction, loss of  mIndy reduces arterial BP and heart rate (HR) by decreasing the sympathoadrenal sup-
port in mice independently of  body composition. Radiotelemetry was used to evaluate the effect of  mIndy 
deletion on BP and HR in young, age-matched, male mINDY-KO and WT mice fed a normal chow diet, 
without differences in body composition. Moreover, we assessed autonomic cardiovascular control using 
state-of-the-art physiological, biochemical, and pharmacological profiling and studied the effect of  the dele-
tion of  mINDY in adrenal glands, ex vivo and in cellular culture in vitro.
Results
Deletion of  mIndy leads to reduced body weight and size but normal body composition. mINDY-KO mice were 
generated as previously described (8). Heterozygous mINDY-KO mice were bred and litters contained 
the expected ratio of  WT and homozygous mINDY-KO mice. Compared with WT littermate controls, 
mINDY-KO mice on a regular chow diet had an approximately 10% lower body weight (BW) at the age 
of  13–14 weeks after a 16-hour fast (Figure 1A), due to a reduction in body size (Supplemental Figure 1A; 
supplemental material available online with this article; https://doi.org/10.1172/jci.insight.136083DS1). 
Fat mass and lean mass did not differ between genotypes, as shown by NMR spectroscopy (Figure 1A). 
These results confirm our previous data (8).
mIndy deletion reduces arterial BP and HR. In order to determine BP, radiotelemetric probes were implant-
ed into the right femoral artery of  12-week-old mice of  both genotypes. Implantation in the femoral artery 
spares carotid and aortic baroreceptors, which are crucial for autonomic cardiovascular control. Animals 
were allowed to recover for 7 days postimplantation, and then intra-arterial BP was assessed over a 3-day 
period. Mean arterial BP was reduced in mINDY-KO mice by 8 mmHg compared with littermate WT mice 
(Figure 1B and Table 1), with similar reductions in diastolic and systolic BP (Supplemental Figure 1, B and 
C, and Table 1). At the same time, HR was reduced by 37 bpm in mINDY-KO mice (Figure 1C and Table 1). 
To rule out that the intra-arterial probe in the femoral artery introduced a bias in physical activity, we assessed 
locomotion and observed that activity was similar between genotypes (Figure 1D and Table 1).
mIndy deletion reduces autonomic support of  BP and baroreflex sensitivity. Concomitant reductions in arterial 
BP and HR suggest autonomic nervous system involvement, specifically a decrease in sympathoadrenal 
tone. Ganglionic blockade with trimethaphan decreased BP (WT = –28 ± 3 ΔmmHg; mINDY-KO = –20 
± 4 ΔmmHg; P < 0.05; Figure 2A) and HR (WT = –266 ± 13 Δbpm; mINDY-KO = –206 ± 16 Δbpm; P < 
0.01; Figure 2B) to a lower extent in mINDY-KO versus littermate WT controls. These in vivo findings are 
consistent with reduced autonomic support of  BP through the sympathetic nervous system with reduction 
in adrenergic vascular tone and perhaps cardiac innervation in mINDY-KO mice.
Dynamic influences of  sympathetic and parasympathetic activity on cardiovascular control can be 
elucidated through BP variability and baroreflex sensitivity measurements. Systolic BP variability in 
the low-frequency band was reduced by 50% with mINDY deletion (LFsys; WT = 4.8 ± 0.6 mmHg2; 
mINDY-KO = 2.4 ± 0.4 mmHg2; Figure 3A; P < 0.05). The increase in LFsys in obese mouse models is 
characterized by increased sympathetic drive (11). Moreover, rapid baroreflex-mediated HR changes in 
mice are primarily mediated through cardiac vagal efferents. Measures that augment vagal activity are 
associated with improved baroreflex sensitivity (11, 12). Here, BRS measured by cross-spectral analysis 
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Figure 1. BW and body 
composition, arterial BP, HR, 
and voluntary activity of mIN-
DY-KO mice and WT littermate 
controls. (A) After a 16-hour 
fast, BW and body composi-
tion were measured in 13- to 
14-week-old mINDY-KO (n = 4) 
and WT littermate control (n = 
3) mice fed a regular chow diet. 
BW and body composition were 
as follows: mINDY-KO (25.2 ± 
0.3 g; 74.74% lean mass and 
12.28% fat mass of BW); WT 
littermates (27.6 ± 1.2 g; 73.6% 
lean mass and 13.3% fat mass 
of BW). mINDY-KO mice had a 
lower BW based on a shorter 
body length compared with WT 
littermate controls. A 2-tailed 
Student’s t test was performed 
to determine significance level 
between groups. Data represent 
the mean ± SEM (*P < 0.05). 
(B–D) Radiotelemetry system 
was used for monitoring arterial 
BP, HR, and voluntary activity 
in mINDY-KO (n = 6) and WT 
littermate control mice (n = 
8) fed a regular chow diet. 
(B) Arterial BP (mINDY-KO 
overall 96 ± 2 mmHg; day, 92 
± 3 mmHg, and night, 99 ± 
3 mmHg. WT overall 104 ± 2 
mmHg; day, 100 ± 3 mmHg, 
and night, 108 ± 1 mmHg). (C) 
HR (mINDY-KO overall 463 ± 
7 bpm; day, 443 ± 9 bpm, and 
night, 484 ± 10 bpm. WT overall 
500 ± 5 bpm; day, 474 ± 5 bpm, 
and night, 526 ± 5 bpm). (D) 
Voluntary activity (mINDY-KO 
overall 10 ± 1 counts/min; day, 5 
± 1 counts/min, and night, 15 ± 
2 counts/min. WT overall 11 ± 1 
counts/min; day, 5 ± 1 counts/
min, and night, 17 ± 1 counts/
min). Mean daily values from all 
animals during a 3-day period 
were analyzed. A 2-way ANOVA 
was performed to determine 
significance level.
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and determined by the sequence method was greater in mINDY-KO compared with WT mice (BRS 
sequp; WT = 2.8 ± 0.4 ms/mmHg; mINDY-KO = 3.8 ± 0.6 ms/mmHg; Figure 3B; BRS seqdown; 
WT = 2.5 ± 0.3 ms/mmHg; mINDY-KO = 3.8 ± 0.5 ms/mmHg; Figure 3C; P < 0.05). These findings 
strongly support the idea that mINDY deletion is associated with a shift of  cardiovascular sympathetic 
and parasympathetic modulation toward parasympathetic predominance.
mIndy deletion attenuates urinary catecholamines and catechloaminergic pathways of  the adrenal gland transcrip-
tome. We further investigated the sympathoadrenal system as a mediator of  the beneficial cardiovascular 
effect of  mINDY deletion. The sympathetic nervous system regulates arterial BP and HR via norepineph-
rine released from postganglionic adrenergic terminals (13, 14). Norepinephrine (NE) and epinephrine (E) 
and their respective O-methylated metabolites, normetanephrine (NMN) and metanephrine (MN), can be 
measured in the circulation or in urine samples collected during a 24-hour period. Because of  difficulties in 
obtaining stress-free peripheral blood, 24-hour urinary catecholamine levels were measured and normalized 
to urine osmolality. Levels of  NE were reduced by 39% and E by 33% in mINDY-KO mice compared with 
WT littermates (Figure 4A). Urinary NMN and MN outputs were also significantly reduced in mINDY-KO 
mice (Figure 4B), strongly indicating lower sympathetic support of  BP with mIndy deletion. These results 
prompted us to perform whole-genome microarray analysis on adrenal tissue samples of  mINDY-KO mice 
and WT littermates because catecholamines are synthesized and released from the adrenal medulla. Unbi-
ased gene set enrichment analysis revealed markedly decreased expression of  pathways regulating catechol-
amine biosynthesis in mINDY-KO versus WT littermates (Figure 4C). Quantitative real-time PCR (RT-PCR) 
was used to confirm gene expression results. Important enzymes in catecholamine biosynthesis such as tyro-
sine hydroxylase (TH) — the rate-limiting step in catecholamine synthesis — DOPA decarboxylase (DDC), 
dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) showed significant 
reductions in mINDY-KO mice (Figure 4D). TH reduction was also verified on a protein level (Supplemental 
Figure 2). In contrast, genes involved in catecholamine degradation like monoamine oxidase (MAO) and 
catechol-O-methyltransferase (COMT) were unaltered between genotypes (Figure 4E).
Catecholamine biosynthesis is reduced by mIndy deletion. Catecholamines are synthesized in sympathetic nerve 
terminals and adrenal medulla (15–19). As a model tissue, adrenal glands were harvested from mINDY-KO 
mice and littermate controls. Adrenal gland weight (Figure 5A) and histological morphology by H&E stain-
ing analysis did not reveal any major differences (Figure 5B). Previous data have suggested that mIndy expres-
sion is relatively high in the liver as compared with other organs such as skeletal muscle, adipose tissue, and 
kidneys (20). Interestingly, we found that the level of  mIndy expression was also high in adrenal tissue (Figure 
5C). Here, medullary Indy gene expression was about 70% higher than in adrenal cortex (Figure 5D). To con-
firm effective separation of  adrenal medulla from cortex, we determined mRNA expression levels of  proto-
typical medullary and cortical genes. In these samples, relative TH expression was 1.19 ± 0.29 AU in adrenal 
Table 1. BP, HR, and locomotor activity in mINDY-KO and WT mice
Parameter WT mINDY-KO Δ (WT – mINDY-KO) (Significance)
Mean arterial BP 
(mmHg)
overall 104 ± 2
day 100 ± 3
night 108 ± 1
overall 96 ± 2
day 92 ± 3
night 99 ± 3
8 (P < 0.01)
8 (P = 0.07)
9 (P < 0.01)
Systolic BP (mmHg)
overall 121 ± 2
day 116 ± 3
night 125 ± 1
overall 113 ± 2
day 108 ± 3
night 117 ± 3
8 (P < 0.01)
8 (P = 0.07)
8 (P < 0.01)
Diastolic BP (mmHg)
overall 89 ± 2
day 84 ± 3
night 93 ± 1
overall 81 ± 2
day 77 ± 4
night 84 ± 3
8 (P < 0.01)
8 (P = 0.13)
8 (P < 0.01)
HR (bpm)
overall 500 ± 5
day 474 ± 5
night 526 ± 5
overall 463 ± 7
day 443 ± 9
night 484 ± 10
37 (P < 0.001)
31 (P < 0.01)
42 (P < 0.001)
Locomotor activity (counts/
min)
overall 11 ± 1
day 5 ± 1
night 17 ± 1
overall 10 ± 1
day 5 ± 1
night 15 ± 2
1 (P = 0.80)
0 (P = 0.66)
2 (P = 0.57)
Significances within this table were analyzed by Student’s t test.
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medulla and 0.11 ± 0.03 AU in adrenal cortex (P < 0.01), and steroidogenic acute regulatory protein (StAR) 
was 0.84 ± 0.07 AU in the adrenal medulla and 3.90 ± 1.23 AU in adrenal cortex (P < 0.06) (Supplemen-
tal Figure 3). These findings support the idea that reduced catecholamine biosynthesis may have attenuated 
peripheral catecholamine availability with mIndy deletion.
Inhibition of  mINDY transport function in chromaffin pheochromocytoma cells reduces catecholamine content. To 
test whether inhibition of  mINDY transporter function is sufficient to reduce catecholamine content, we 
treated the chromaffin pheochromocytoma cell line mouse pheochromocytoma cells (MPCs) with the mIN-
DY inhibitor PF-06761281 (21). This small molecule inhibitor reduces mINDY-mediated citrate uptake in 
mouse hepatocytes with an IC50 of  0.21 μM and lowers fasting glucose levels and urinary citrate excretion in 
high-fat diet–induced obese mice (21). We first assessed citrate uptake in MPCs with and without 1 μM of  
PF-06761281 and found a significant approximately 35% reduction in the presence of  the mINDY inhibitor 
(P < 0.001, Figure 6A). Preincubation of  MPC cells with 5 mM sodium citrate increased cellular NE, DOPA, 
and dopamine content in MPC cells after normalization to cell number, an effect that was partially blunted 
by addition of  1 μM PF-06761281 before and during citrate treatment (Figure 6B). Previous report showed 
that PF-06761281 dose-dependently lowers citrate uptake in the liver, kidney, and testis with IC50 values of  
1.4, 1.0, and 1.0 μM, respectively, while IC50 values in human hepatocytes are 0.74 μM and in mouse hepato-
cytes 0.21 μM (21, 22). Taken together, the reduction in catecholamine content appears to be directly linked 
to mINDY-mediated citrate transport function. Of note, catecholamine content in absence or presence of  
the inhibitor was normalized to the viable cell number (Figure 6B) to exclude possible effect of  cell viability.
Steroid hormones, vascular relaxation, and cardiac function are not changed with deletion of  mIndy. Adrenal 
glands also synthesize steroid hormones, such as aldosterone, which affects arterial BP, but not HR. More-
over, cholesterol is the first building block of  steroids, and citrate, the main substrate of  mINDY, can be 
used to generate cholesterol. Next, we assessed whether mIndy deletion can reduce steroid hormone levels 
and synthesis. Circulating steroid hormone concentrations did not show significant differences between 
genotypes (Figure 7A), and microarray analysis showed similar expression levels of  genes important in 
steroid hormone synthesis regardless of  the genotypes. These results were also verified by RT-PCR (Figure 
7B). Moreover, rate-limiting enzymes of  sterol (StAR) and aldosterone synthesis (CYP11B2 or aldosterone 
synthase) were unaltered between genotypes (Supplemental Figure 2).
To address local vascular tone, vascular smooth muscle constriction in response to potassium and NE 
was measured ex vivo. Also, endothelial function was assessed by measuring maximum aortic ring relax-
ation using cumulative increasing concentrations of  acetylcholine (ACh) in aortic rings precontracted 
by phenylephrine ex vivo (Supplemental Figure 4 and Supplemental Table 1). Aortic ring diameters and 
Figure 2. BP and HR in response to trimethaphan. mINDY-KO (n = 3) and littermate WT control mice (n = 5) were treated with trimethaphan (120 mg/kg BW) 
followed by the measurement of (A) individual BP response (mINDY-KO, –34 ± 10 ΔmmHg; WT, 28 ± 3 ΔmmHg) and (B) HR (mINDY-KO, –210 ± 15 Δbpm; WT, 
–266 ± 13 Δbpm). Changes in HR and BP are expressed as change relative to baseline (measured over a time frame of 1200 seconds). Values of 2 different 
time frames of 1200 seconds each (2400 seconds in total) were analyzed per animal. A 2-tailed Student’s t test was performed to determine significance level 
between groups. Data represent the mean ± SEM (*P < 0.05; **P < 0.01).
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vessel tone were similar in the 2 genotypes (Supplemental Table 1). These data do not support the idea 
that changes in vascular structure or responsiveness contributed to changes in BP with mIndy deletion. 
Finally, developmentally induced structural changes in the heart itself  can largely contribute to changes 
in BP and HR. We therefore assessed cardiac function in vivo by echocardiography in mINDY-KO, 
WT littermate, and additional weight-matched WT control mice. The last group was included because 
mINDY-KO mice showed a lower body length and weight compared with WT littermates, which may 
affect echocardiographic measurements (Supplemental Figure 1A and Supplemental Figure 5A). Of  sig-
nificance, in vivo echocardiography of  mice under anesthesia led to similar HRs between the 3 exper-
imental groups (Supplemental Figure 5B). In this setting, ejection fraction (Supplemental Figure 5C), 
stroke volume (Supplemental Figure 5D) and strain (Supplemental Figure 5, E and F), as well as fraction-
al shortening, cardiac output, end-diastolic- and end-systolic volume, and end-diastolic and end-systolic 
left ventricle mass (Supplemental Figure 6, A–F) were similar between mINDY-KO and weight-matched 
WT control mice, used as the correct control group instead of  WT littermates, indicating that there were 
no cardiac structural abnormalities associated with the deletion of  mIndy and that no morphological 
changes accounted for the observed phenotype. Last, analysis of  heart morphological structure by H&E 
staining was similar between mINDY-KO and WT littermate controls (Supplemental Figure 7).
Figure 3. Systolic BP variability and baroreflex sensitivity. Systolic BP 
variability in the frequency range and baroreflex sensitivity (BRS) were 
calculated by cross-spectral analysis (BRS-LF) or by the sequence tech-
nique (BRS sequp, BRS seqdown) in mINDY-KO (n = 5) and littermate 
WT controls (n = 5) at the age of 3–4 months. Time length measure-
ment was similar between genotypes (WT, 3665 ± 137 s; mINDY-KO, 
3694 ± 133 s). (A) LFsys (WT, 4.8 ± 0.7 mmHg2; mINDY-KO, 2.4 ± 0.4 
mmHg2); (B) BRS sequp (WT, 2.8 ± 0.4 ms/mmHg; mINDY-KO, 3.8 ± 0.6 
ms/mmHg). (C) BRS seqdown (WT, 2.5 ± 0.3 ms/mmHg; mINDY-KO, 
3.8 ± 0.5 ms/mmHg). Significance level was determined by a 2-tailed 
Student’s t test. Data represent the mean ± SEM (*P < 0.05).
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Figure 4. Urinary catecholamines, metanephrines, and 
adrenal gland transcriptomics. (A) Urinary secretion 
of NE and E in mINDY-KO (n = 9; NE, 0.12 ± 0.02, and 
E, 0.02 ± 0.003 nmol × kg/mmol × L Osmo) and WT 
littermate control mice (n = 9–11; NE, 0.31 ± 0.02, and 
E, 0.06 ± 0.006 nmol × kg/mmol × L Osmo). (B) Urinary 
secretion of NMN and MN in mINDY-KO (n = 9; NMN, 
0.48 ± 0.05, and MN, 0.03 ± 0.004 nmol × kg/mmol × 
L Osmo) and WT littermate control mice (n = 11; NMN, 
1.36 ± 0.05, and MN, 0.09 ± 0.014 nmol × kg/mmol × L 
Osmo). (C) Adrenal gland gene set enrichment analysis 
in mINDY-KO (n = 5) and littermate control mice (n = 6) 
fed a regular chow diet. (D) Relative gene expression of 
catecholamine biosynthetic enzymes and (E) enzymes 
involved in catecholamine degradation in adrenal 
glands of mINDY-KO (n = 12–13) and WT littermate 
controls (n = 15). Significance level was determined by 
a 2-tailed Student’s t test. Data represent the mean ± 
SEM (*P < 0.05; **P < 0.01; ***P < 0.001).
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Discussion
In this study, deletion of the longevity gene mIndy (Slc13a5) lowered BP and HR as measured by radioteleme-
try. Pharmacological and biochemical profiling revealed that mIndy affects long-term BP regulation through a 
potentially novel mechanism regulating sympathoadrenal tone and catecholamine biosynthetic pathways. Con-
comitant reductions in arterial BP and HR suggested that the response was mediated by a common mechanism. 
Indeed, the depressor response to ganglionic receptor blockade with trimethaphan was attenuated, indicating 
reduced sympathoadrenal signaling to the periphery. In addition, oscillations of systolic BP in the low-frequen-
cy band, which are mediated through the sympathetic nervous system (11), were reduced. Moreover, BRS was 
increased in mINDY-KO mice, which typically occurs with a shift of  the balance between sympathetic and 
parasympathetic activity toward parasympathetic predominance in vivo (11, 23–25). The sympathetic nervous 
system regulates BP and HR via the release of catecholamines from adrenergic terminals, which can then be 
detected in 24-hour collected urine of mice. Catecholamine concentrations in the urine of mINDY-KO mice 
were reduced when compared with WT controls. Unbiased microarray analysis of mINDY-KO adrenal glands 
showed a reduction in the pathways involved in catecholamine synthesis, such as TH, the rate-limiting step in 
catecholamine biosynthesis. The results were confirmed by RT-PCR and immunoblotting. Citrate treatment 
increased global catecholamine biosynthesis in the adrenal pheochromocytoma cell line MPC, an effect that 
was partially blunted by inhibition of mINDY with a small molecule inhibitor, previously shown to reduce 
citrate uptake and to improve metabolic control in obese mice in vivo (21). Together, these data suggest that 
mIndy has an important function in cardiovascular control by reducing sympathoadrenal support of arterial BP.
Centrally generated efferent sympathetic activity is transmitted through postganglionic nerve fibers to 
peripheral organs, including blood vessels and the heart (26). Ganglionic blockade with trimethaphan vir-
tually abolishes postganglionic adrenergic traffic (11, 27). The reduced depressor response to trimethaphan 
in mINDY-KO mice is consistent with attenuated tonic support of  blood pressure through the sympa-
thetic nervous system. Indeed, low-frequency band oscillations of  arterial BP, which are mainly mediated 
through the sympathetic nervous system, were also reduced in mINDY-KO mice. Catecholamine-secreting 
Figure 5. Adrenal gland weight, histology, and Indy gene expression. (A) Left and right adrenal gland weight in mINDY-KO (n =14–15) and WT littermate control 
(n = 13) mice. WT (left, 1.66 ± 0.057 mg; right, 1.48 ± 0.048 mg); mINDY-KO (left, 1.69 ± 0.059 mg; right 1.55 ± 0.055 mg). (B) Histological analysis of mINDY-KO (n 
= 3) and WT littermate control mice (n = 3). A representative H&E-stained section is shown per genotype. (C) Liver, epigonadal white adipose tissue, and adrenal 
gland Indy gene expression in WT mice (n = 13). (D) Adrenal medulla and cortex Indy gene expression in WT mice (n = 6). Significance level was determined by a 
2-tailed Student’s t test in A and D (**P < 0.01). Significance level was determined by a 1-way ANOVA in C (**P < 0.01). Data represent the mean ± SEM.
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cells including adrenal medullary cells convert tyrosine serially to l-DOPA and dopamine, which is con-
verted further to NE and E; both are stored within secretory vesicles (28, 29).
Citrate can serve as a substrate for fatty acid synthesis, and the acetyl moiety of  the intermediate ace-
tyl-CoA can be used for histone acetylation, which is critical regulator of  gene expression. Citrate is also 
known to inhibit glycolysis by inhibiting phosphofructokinase-1 and activate gluconeogenesis by stimu-
lating fructose-1,6-bisphosphatase (30). Moreover, inhibition of  citrate uptake by mIndy deletion results 
in AMPK activation and increased mitochondrial activity (8, 31). Mitochondrial respiratory activity is 
involved in several aspects of  catecholamine synthesis and secretion in adrenal samples from patients with 
pheochromocytoma (32) but also in physiological adrenal responses to stress in mice (33). Overall, we 
hypothesize that the interaction between transcriptional epigenetic regulation and a change in cellular ener-
gy levels contributes to the effect of  citrate on catecholamine synthesis and secretion.
In mice, cumulative systemic catecholamine secretion is best reflected by 24-hour collected urine mea-
surements. Blood drawing in mice is associated with stress, leading to immediate release of  stress hormones, 
such as catecholamines, that can confound the analysis of  catecholamine secretion. In our study, 24-hour 
collected urine specimens showed that NE and E as well as their degradation products NMN and MN 
Figure 6. Citrate stimulation and mINDY transport inhibition affect 
catecholamine biosynthesis in adrenal MPC cells. (A) 14C-Citrate uptake 
in the pheochromocytoma cell line MPC treated for 30 minutes with and 
without 1 μM of the mINDY inhibitor, PF-06761281. (B) MPCs were treated 
with 5 mM sodium citrate or 1 μM PF-06761281, alone or combined, for 72 
hours. Lysates were prepared for the determination of NE, 3,4-dihydroxy-
phenylalanine (DOPA), dopamine (DA), and 3,4-dihydroxyphenylacetic 
acid (DOPAC) levels. Significance level was determined by a 2-tailed Stu-
dent’s t test in A (***P < 0.001). A 2-way ANOVA was performed in B to 
determine significance level between groups (*P < 0.05; ****P < 0.001). 
Data represent the mean ± SEM.
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Figure 7. Plasma steroids and steroid hormone synthesis. (A) Measurement of circulating steroid hormone concentrations in mINDY-KO (n = 9) and WT 
littermate control mice (n = 9). (B) Adrenal gland gene expression analysis by RT-PCR of enzymes important for steroid hormone synthesis in mINDY-KO (n 
= 14–15) and WT littermate controls (n = 12–13). A 2-tailed Student’s t test was performed to determine significance level between groups. Data represent 
the mean ± SEM (*P < 0.05; ***P < 0.001).
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were robustly reduced in mINDY-KO mice, indicating a strong effect of  mIndy on catecholamine synthesis 
and extraneuronal and adrenal medullary catecholamine metabolism. In line with these observations, we 
noticed relatively high mIndy expression in the adrenal medulla compared with other organs and tissues. 
Moreover, unbiased, whole-genome, microarray-based analysis of  the adrenal glands of  mINDY-KO and 
WT littermate controls showed reduced catecholamine biosynthetic processes. These findings were con-
firmed by RT-PCR and protein analysis of  genes coding for several rate-limiting enzymes in catecholamine 
biosynthesis, TH, DDC, DBH, and PNMT. In contrast, expression of  genes coding for adrenal catechol-
amine-degrading enzymes such as MAO and COMT were unaltered. Incubation of  MPC cells with citrate, 
the main mINDY transporter substrate, markedly increased catecholamine level in these cells, an effect 
blunted by pharmacological inhibition of  mINDY. Together, these data suggest that mINDY interacts with 
the sympathoadrenal system at least in part through catecholaminergic pathways.
Cardiovascular and metabolic diseases are tightly linked as exemplified by the metabolic syndrome, 
which comprises abdominal adiposity, altered glucose and lipid metabolism, increased BP, and often high-
er HR (34). Many individuals with obesity or type 2 diabetes are hypertensive, an observation consistent 
with a solid crosstalk between cardiovascular and metabolic control mechanisms. Deletion of  mIndy has 
previously been shown to improve metabolic disease, such as diet-induced obesity, insulin resistance, and 
nonalcoholic fatty liver disease in mice (5, 8, 9, 22). The cardiovascular phenotype in our study implicates 
a role of  mIndy in this cardiometabolic crosstalk. Reduction of  BP in mINDY-KO mice could be mediated 
through direct mINDY actions or via indirect influences on BP control through changes in body compo-
sition. Here, mice were fed a normal chow diet, which excluded the contribution of  body composition 
changes, specifically fat mass, in BP regulation between both genotypes. Confirming previous reports, mIN-
DY-KO mice were slightly smaller and thus had reduced BWs (8). Otherwise, mINDY-KO mice showed 
similar proportions of  fat and lean mass compared with their littermate controls as assessed with NMR in 
vivo. Therefore, differences in body composition do not explain our findings. Moreover, smaller animals 
tend to have higher HRs than larger ones, which is not seen in the mINDY-KO mice (35–38).
We also note that in mINDY-KO mice the vascular responsiveness toward adrenergic stimulation with 
phenylephrine was unaffected ex vivo, suggesting that the change in BP was mediated through altered 
catecholamine release rather than changes in vascular α-adrenoceptor responsiveness. Furthermore, potas-
sium-induced vasoconstriction did not differ between mINDY-KO and WT littermate controls, indicating 
that smooth muscle constrictor functions were unchanged in KO mice. In vivo echocardiography revealed 
similar ejection fraction, stroke volume, and cardiac output and strain when HR was controlled by anesthe-
sia and when mINDY-KO mice were compared with weight-matched WT control mice. These data indi-
cate that deletion of  mIndy is not associated with structural and/or functional abnormalities in the heart.
Our study cannot fully exclude that other mechanisms also contributed to changes in cardiovascular 
autonomic control. For example, reduced synthesis of  steroid hormones such as aldosterone could con-
tribute to the response. However, steroid hormone levels were not different between mINDY-KO and WT 
mice, and genetic as well protein levels of  the major enzymes involved in steroid hormone synthesis were 
not changed. Because mINDY is expressed predominantly in the adrenal medulla, we hypothesize that cat-
echolamines are more affected than steroid hormones. Reduced expression of  catecholamine-synthesizing 
enzymes supports this idea. Our data on the pheochromocytoma cells show that citrate, the main mINDY 
substrate, increased catecholamine content, while pharmacological inhibition of  citrate uptake blunted this 
effect, making developmental effects of  mINDY on catecholamine synthesis unlikely.
We did not observe structural or functional changes in the heart with histological analysis of  myo-
cardial tissue or echocardiography in vivo. Of  note, echocardiography was performed during anesthesia, 
which led to similar HRs between mice. An additional challenge, such as pressure overload or myocardi-
al infarction, may be required to unmask influences of  mINDY on cardiac structure. Future studies are 
needed to address this important point.
To exclude variations in physiological responses by hormonal fluctuations in female mice, we have 
used male mice throughout the study (39–44). The selection of  male mice represents a limitation of  our 
study, and more studies are needed to show that the observed effects are also present in female mice.
Reducing Indy gene expression leads to longevity in lower organisms and to a phenotype akin to 
caloric restriction in mice, an intervention that is well known to induce longevity in most species (6–8). 
Interestingly, reduced sympathetic activity and lower BP are associated with cardiovascular protection 
and prolonged life span (45, 46). Longevity studies in mINDY-KO mice will be extremely interesting. 
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It will be important to determine whether the hypotensive effect of  mIndy will be present also in aged mice 
and how this translates into cardiovascular morbidity and mortality.
Deletion or reduction of  mIndy/mINDY has been shown to be protective against diet-induced meta-
bolic disorders, including obesity, insulin resistance, and nonalcoholic fatty liver disease (5, 8–10). Obe-
sity in general goes along with increased sympathetic activity (47–50). Here, we added potentially novel 
pieces to generate a more complete picture of  the benefits of  decreasing mINDY activity by showing that 
deletion of  mIndy also affects arterial BP and HR by reducing sympathoadrenal activity. Remarkably, 
recent genome-wide association studies suggested that the Slc13a5 polymorphism rs16956192 contributes 
to variability in arterial BP (51). In addition to providing a potentially novel mechanism contributing to 
cardiometabolic crosstalk, our study further supports mINDY as a promising target for the whole spec-
trum of  metabolic syndrome components, including increased BP.
Methods
Animals. Mice were generated as described (8): pups carrying the SLC13A5tm1.1Helf allele were genotyped at 
the expected frequency of  about 25%. Mice carrying SLC13A5tm1.2Helf allele (Δ1-6) were obtained by mating 
SLC13A5tm1.1Helf/+ mice with animals carrying Hprt1-Cre transgene: 129S1-Hprttm1(Cre)Mnn (The Jackson 
Laboratory). The offspring was then backcrossed more than 10 times to the C57B/6J background, and 
studies were performed with age-matched littermate control WT mice. Homozygous mINDY-KO mice 
were obtained from mating heterozygous mINDY-KO mice. Littermate animals were used in all exper-
iments; however, for echocardiography we also used WT mice (Charles River Laboratories) that were 
weight matched to mINDY-KO mice as a third experimental group. All breeding and procedures were 
carried out at the animal facilities of  the Charité Berlin and Technical University Dresden according to 
institutional regulations and the local guide for the use and care of  laboratory animals.
Experiments based on BP measurements by telemetry were performed on 12- to 16-week-old mIN-
DY-KO male mice and littermate controls. We have selected male mice to exclude variations in physiolog-
ical responses by hormonal fluctuations of  estrogen and progesterone in female mice (39–44). The animals 
had free access to standard chow (0.25% sodium, SNIFF GmbH, Soest, Germany) and drinking water ad 
libitum. Animals were cared for within the Institutional Animal Care Committee guidelines, and all animal 
procedures were approved by local government authorities.
Analysis of  body composition. Body composition was analyzed before and after BP studies using proton NMR 
(1H-MRS), and adipose tissue mass was quantified in vivo using micro-computed tomography. After studying 
telemetry, spectral analysis, baroreceptor HR reflex, sequence technique, BRS, pharmacological testing, and echo-
cardiography (as described below), mice were anesthetized for the harvest of various tissues and organs including 
heart, aorta, adrenal glands, brain, skeletal muscle, epigonadal and subcutaneous adipose tissues, and liver.
Telemetry. Before implantation of  the TA11PA-C20 BP device (Data Sciences International), the zero 
offset was measured, and the unit was soaked in 0.9% NaCl. Mice were anesthetized with isoflurane 
(Cura Med Pharma). The pressure-sensing catheter was advanced via the right femoral artery into the 
abdominal aorta, and the transmitter was placed in a subcutaneous pocket along the right flank. During 
surgery and in the recovery period, the mice were placed on a heated table to maintain body temperature. 
The mice were synchronized to a 12-hour light/12-hour dark schedule with lights on at 6:00 am. All 
mice were allowed a 7-day recovery from surgery before baseline BP and HR values were recorded for 3 
days. By this time, the mice had regained their circadian BP and HR rhythms, and the surgery and anes-
thesia-dependent initial changes in BP and HR were followed by stabilization of  both values. The mice 
received a normal chow diet and tap water (0.25% NaCl).
The data from the TA11PA-C20 device were transmitted via radio frequency signals to a receiver below 
the home cage and thereafter collected using the DATAQUEST ART system, version 2.1 (Data Sciences 
International), which allowed us to detect, collect, and analyze signals from several animals simultaneously. 
The data were sampled every 5 minutes for 10 seconds continuously with a sampling rate of  1000 Hz and 
stored on a hard disk. Systolic and diastolic BP, mean arterial pressure (MAP), and HR were recorded using 
the DATAQUEST software (ART 2.1). HR was computed from the pulse intervals of  the BP recordings. For 
statistical analysis, we used 3 days of  baseline values. Rhythm analysis for 27-hour periods in individual mice 
were performed using DQFIT program, which calculates the amplitude and the acrophase of  both param-
eters (52). Activity was monitored as changes in transmitter signal strength due to the mouse (transmitter) 
locomotion. For further evaluation of  cardiovascular function, the baroreceptor HR reflex was investigated 
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using spontaneous changes in BP and HR. For this purpose, beginning after the 3 days of  baseline values, 
BP waveforms were stored in a beat-by-beat modus 1 hour before and 1 hour after intraperitoneal injections 
of  different drugs for pharmacological blockade of  the autonomic nervous system. Beat-by-beat BP and HR 
values were obtained from these continuously recorded data.
Autonomic blockade. To evaluate autonomic control of  BP in mINDY-KO and WT littermate control mice, 
continuous beat-by-beat values of  BP and HR were recorded for 1 hour, after which the animals were admin-
istered the ganglionic blocker trimethaphan at a dose of  120 mg/kg intraperitoneally. Continuous beat-by-beat 
values of  BP and HR were recorded for 1 additional hour. Handling caused an HR and MAP increase in both 
strains, which decreased over time following trimethaphan injection. Forty-five minutes after the injection of  
saline, MAP and HR were comparable to baseline values. Therefore, the values 1 hour after drug injection 
were used to characterize the trimethaphan response. Because of  the drug’s pharmacodynamics, the effects 
were determined at the nadir of  the HR and BP responses, between 7 and 12 minutes after injection (53). The 
time ranges for calculating HR and BP changes were the same. HR variability and baroreceptor function were 
also determined in steady-state conditions to exclude stress-induced BP and HR changes.
Spectral analysis and BRS. For evaluation of  cardiovascular function, the baroreceptor HR reflex was 
investigated using spontaneous changes in BP and HR. The power spectra of  systolic BP, pulse interval 
time series, and the cross spectra were calculated using fast Fourier transformation (FFT) (54–58). The 
power spectral density was estimated by the Welsh method with FFT length of  512 sample points, interpo-
lation, resampling with 12 Hz, linear trend elimination, and Hanning window. The data analysis was per-
formed with the PV-wave software (Visual Numerics). Five representative intervals were chosen and aver-
aged according to the following criteria: 1) steady-state conditions, 2) no large and sudden BP changes, and 
3) no artifacts. The frequency bands were adapted for analysis in mice considering the ranges of  HR and 
breathing frequencies (low frequency about 0.25–1.0 Hz, high frequency about 1.0–6.0 Hz). Low-frequency 
components of  pulse interval spectrum (LF), high-frequency components of  pulse interval spectrum (HF), 
LF/HF ratio, low-frequency power of  systolic BP (SBP-LF), and root mean square of  successive differenc-
es between adjacent normal pulse intervals were calculated. The baroreflex gain (BRS-LF) was determined 
as mean value of  the transfer function between systolic BP and pulse intervals in the low-frequency band. 
BRS was considered significant if  the coherence in the analyzed frequency band was about 0.8.
MPC cell culture. MPCs generated from heterozygous neurofibromatosis KO mice were acquired from 
Arthur Tischler (New England Medical Center and Tufts University School of  Medicine, Boston, Massa-
chusetts, USA) (59). MPC cells were seeded on collagen A–coated cell culture dishes (60) and maintained 
in RPMI-1640 medium containing 10% horse serum and 5% fetal calf  serum supplemented with 2 mM 
GlutaMAX (complete medium). Collagen, RPMI, and GlutaMAX were from Thermo Fisher Scientific. 
Cells were cultured at 37°C, 5% CO2, and 95% humidity. MycoAlert Mycoplasma Detection Kit (Lonza, 
Switzerland) was used to ensure that cells were mycoplasma free. After trypsinization (trypsin/EDTA; 
0.05%/0.02%) cells were diluted with complete medium and counted using the Neubauer counting cham-
ber. All experiments were performed free of  antibiotics for at least 1 passage after recultivation.
Radiolabeled C14-citrate uptake in MPC cells. 14C citric acid (Hartmann, 114 μCi/mmol) was dissolved in 
uptake buffer (140 mmol/L NaCl, 1 mol/L KCl, 1 mol/L CaCl2, 1 mol/L MgSO4, 550 mmol/L glucose, 1 
mol/L HEPES), and unlabeled citric acid was added to the final concentration mentioned. MPCs (50,000 
cells/well, 48-well dishes) were incubated with the uptake solution in the absence or presence of  1 μM of  
the mINDY inhibitor PF-06761281 (Pfizer) for 10 minutes at 37°C as described (61). Cells were washed 
3 times with ice-cold uptake buffer, lysed with 0.2% SDS. The intracellular radioactivity was detected by 
liquid scintillation counting (PerkinElmer Life Sciences). For each concentration 3 to 6 wells were used for 
each concentration of  radiolabeled citrate. The specific mINDY-mediated citric acid uptake was obtained 
by subtracting off  the nonspecific uptake measured in the presence of  PF-06761281.
Catecholamine measurements in MPCs. MPCs were seeded in 24-well plates at a density of  1.5 × 105 cells/
well (4 replicates for each condition). Once attached, cells were treated with vehicle (control), 5 mM sodi-
um citrate, or 5 mM sodium citrate combined with 1 μM of  the INDY inhibitor PF-06761281 (Pfizer). Cells 
were incubated for 72 hours, then washed with PBS, and 3 wells per condition were extracted by adding 
100 μL 0.4 M perchloric acid containing 0.5 mM EDTA. The remaining well was used for normalization 
by counting the corresponding cell number (Neubauer chamber). After centrifugation to remove cell debris, 
supernatants were stored at –80°C. Catecholamines were analyzed by liquid chromatography with electro-
chemical detection as described previously (62).
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MPC proliferation, cell viability, and apoptosis assays. For evaluation of  cell proliferation, cells were count-
ed by using the Neubauer chamber 24, 48, and 72 hours after seeding. CellTiter AQueous One Solution 
Cell Proliferation Assay (Promega) was used to determine the number of  viable cells. For analyzing pro-
grammed cell death, we employed the Caspase 3/7 Assay (Promega), which provides a profluorescent sub-
strate with an optimized bifunctional cell lysis/activity buffer for caspase-3/7 (DEVDase) activity assays 
(60). All assays were performed according to the manufacturer’s protocols and guidelines.
Ex vivo analysis of  vascular function. Vascular function was analyzed in aortic segments using a Mulvany 
myograph (56). First, the basal tone in the 2 experimental groups (mINDY-KO and WT littermate controls) 
was measured after applying 20 mmHg distension to aortic segments. Vessels were preconstricted with a 
potassium-enriched solution or phenylephrine (PE). Endothelial function was analyzed in aortic rings after 
precontraction with 0.3 mmol/L PE and subsequent relaxation in response to increasing concentrations 
of  ACh. The level of  ACh-induced relaxation mediated by nitric oxide (NO) was determined using NO 
synthase inhibitor l-NAME. To analyze vascular smooth muscle relaxation, the NO donor sodium nitro-
prusside was added to PE-precontracted aortic segments.
Vascular function was assessed as described previously (63, 64). In brief, the thoracic aortas were excised 
and cleaned of adherent fat and connective tissue. The length of proximal aortic segments was determined using 
a calibrated ocular micrometer. Aortas were mounted on 2 pins (200 mm diameter) in a Mulvany myograph 
410A (DMT A/S). One pin was attached to an isometric force transducer; the other was attached to a microm-
eter screw, allowing for control of the inner diameter of the vessel preparation. All segments were continuously 
gassed with carbogen (5% CO2, 95% O2) in Krebs-Henseleit buffer in the presence of 10 mmoL/L diclofenac. 
Temperature was set to 37°C. Data are presented as sigmoidal concentration response curves (GraphPad Prism 
6.0, GraphPad Software, Inc.). Effects of ACh are expressed as percentage PE-induced precontraction.
Echocardiography. Transthoracic echocardiography in all experimental groups (WT n = 5, mINDY-KO 
n = 6, weight matched n = 5) was performed in anesthetized animals (2% isoflurane) via an oxygen mask. 
Respiration, temperature, and echocardiography were continuously monitored during the whole scans. Rectal 
temperature was maintained at approximately 38°C by a heated platform. Hair was removed from the abdo-
men by a clipping machine and depilatory cream. Prewarmed gel was used as an ultrasound-coupling medi-
um. Cardiac function and morphology were assessed by echocardiography with a Visual Sonics Vevo 770 
High-Resolution Imaging System with the use of  a high-resolution (40 MHz) transducer. Stroke volume and 
cardiac output were measured by tracing the endocardium in systole and diastole of  a parasternal long-axis 
view of  the left ventricle. All images were acquired and stored for off-line analysis by a blinded observer using 
Visual Sonics Vevo Strain software (Version 2.2.0). B-Mode cine loops were used in parasternal long view to 
assess basic parameters for systolic function (ejection fraction, fractional shortening, end-diastolic volume, 
end-systolic volume, stroke volume, cardiac output, and left ventricular mass) and more accurate and robust 
speckle tracking analysis (global longitudinal strain, global longitudinal strain rate). Negative values illustrate 
fiber shortening of  the myocardium. Images were checked for quality with regard to differentiation of  wall 
borders and absence of  artifacts. Left ventricle endocardium was traced manually in parasternal long-ax-
is views in end-diastole. The epicardium was automatically traced by the software, checked, and manual-
ly adjusted if  necessary for maximum tracking accuracy. Analysis was performed on 3 consecutive cardiac 
cycles, and mean values from the 3 measurements were calculated. Global strain values were obtained from 
the average of  the 6 segments of  the left ventricle.
Catecholamine profiling by liquid chromatography-tandem mass spectrometry. To determine urinary catechol-
amine, metanephrine, and steroid levels, a subset of  WT (n = 9) and mINDY-KO (n = 9) mice were housed 
in individual metabolic cages. After 1 day of  adaptation, urine was collected for 24 hours over the next 2 
days. Only animals with comparable urine volume were included in the study for further analysis.
Measurements of  steroid hormones were batch analyzed by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) as described previously (65). Urinary catecholamines as NE and E and 
their O-methylated free metabolites NMN and MN were simultaneously determined by LC-MS/MS, as 
described previously (66). For the latter, urinary osmolality was used for correction of  different sample vol-
umes. Quantification of  hormone levels was done by comparing ratios of  analyte peak area obtained from 
samples to the respective peak area of  stable isotope-labeled internal standard calibrators.
Adrenal gland and heart histology. Adrenal glands and hearts of  mINDY-KO (n = 3) and WT littermate 
control mice (n = 3) were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Then, 3 × 5 
μm sections per tissue were placed on 1 slide and stained with H&E. Whole adrenal gland and heart were 
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analyzed using the mosaic function of  ApoTome microscope Observer.Z1 (Carl Zeiss). Images were taken 
at 10×, 20×, and 40× original magnification.
Gene expression. Microarray (NCBI Gene Expression Omnibus datavase accession number GSE124886) and 
RT-PCR techniques were carried out according to standard procedures to determine the effect of mINDY-KO on 
gene expression in mouse adrenal glands. Full methodological details are described in Supplemental Methods.
Statistics. Data are presented as means ± SEM. If  not stated otherwise, statistically significant differences 
in mean values were evaluated by Student’s t test (2 tailed) and ANOVA (2 way). Slopes and intercepts of data 
sets were tested for significance using Microsoft Excel and GraphPad Prism. The method is equivalent to an 
analysis of covariance (ANCOVA). P values of less than 0.05 were considered statistically significant. Outliers 
were detected using the 2-sided Grubb’s method.
Study approval. All animal experiments were approved by the local government authorities (Landesamt 
für Gesundheit und Soziales, Berlin, Germany, and Landesdirektion Sachsen, Dresden, Germany).
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